Cracking The Code: Understanding Analyst Reviews For Neurocrine Biosciences
Analysts' ratings for Neurocrine Biosciences (NASDAQ:NBIX) over the last quarter vary from bullish to bearish, as provided by 16 analysts.The table below offers a condensed view of their recent
Neurocrine Price Target Raised to $173.00/Share From $169.00 by JP Morgan
Neurocrine Price Target Raised to $173.00/Share From $169.00 by JP
Neurocrine Is Maintained at Overweight by JP Morgan
Neurocrine Is Maintained at Overweight by JP
JP Morgan Maintains Overweight on Neurocrine Biosciences, Raises Price Target to $173
JP Morgan analyst Anupam Rama maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Overweight and raises the price target from $169 to $173.
Neurocrine Biosciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 19.77% JP Morgan $169 → $173 Maintains Overweight 06/12/2024 10.77% Morgan Stanley $160 → $160
J.P. Morgan Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Raises Target Price to $173
J.P. Morgan analyst Anupam Rama maintains $Neurocrine Biosciences(NBIX.US)$ with a buy rating, and adjusts the target price from $169 to $173.According to TipRanks data, the analyst has a success
Buy Rating Affirmed for Neurocrine Biosciences on Strong Drug Pipeline and Promising Schizophrenia Treatment Prospects
Barclays Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $169
Barclays analyst Carter Gould maintains $Neurocrine Biosciences(NBIX.US)$ with a buy rating, and maintains the target price at $169.According to TipRanks data, the analyst has a success rate of 57.7%
Express News | Neurocrine Biosciences Inc : JP Morgan Raises Target Price to $173 From $169
Jefferies Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $175
Jefferies analyst Akash Tewari maintains $Neurocrine Biosciences(NBIX.US)$ with a buy rating, and adjusts the target price from $182 to $175.According to TipRanks data, the analyst has a success
Express News | Neurocrine Biosciences Inc : RBC Cuts Target Price to $136 From $141
RBC Cuts Price Target on Neurocrine Biosciences to $136 From $141, Keeps Sector Perform Rating
Neurocrine Biosciences (NBIX) has an average investment rating of outperform among analysts polled by Capital IQ, with price targets ranging from $111 to $216.
Neurocrine Biosciences Insider Sold Shares Worth $1,401,864, According to a Recent SEC Filing
Julie Cooke, Chief Human Resources Officer, on July 01, 2024, sold 10,000 shares in Neurocrine Biosciences (NBIX) for $1,401,864. Following the Form 4 filing with the SEC, Cooke has control over a tot
Neurocrine Biosciences(NBIX.US) Officer Sells US$1.4 Million in Common Stock
$Neurocrine Biosciences(NBIX.US)$ Officer Cooke Julie sold 10,000 shares of common stock on Jul 1, 2024 at an average price of $140.1864 for a total value of $1.4 million.Source: Announcement What is
Neurocrine Biosciences(NBIX.US) Officer Sells US$37,565.92 in Common Stock
$Neurocrine Biosciences(NBIX.US)$ Officer Delaet Ingrid sold 272 shares of common stock on Jul 1, 2024 at an average price of $138.11 for a total value of $37,565.92.Source: Announcement What is state
Citi Maintains Neurocrine Biosciences(NBIX.US) With Hold Rating, Maintains Target Price $150
Citi analyst David Hoang maintains $Neurocrine Biosciences(NBIX.US)$ with a hold rating, and maintains the target price at $150.According to TipRanks data, the analyst has a success rate of 59.0% and
Maintaining Hold on Neurocrine Biosciences Amid Efficacy Concerns and Competitive Pressures
Form 144 | Neurocrine Biosciences(NBIX.US) Officer Proposes to Sell 150.06K in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Neurocrine Biosciences(NBIX.US)$ Officer INGRID DELAET intends to sell 1,090 shares of its common stock on Jul 1, with a total market value of approximately $150.06K.
Form 144 | Neurocrine Biosciences(NBIX.US) Officer Proposes to Sell 1.38 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jul 1, $Neurocrine Biosciences(NBIX.US)$ Officer JULIE SMITH COOKE intends to sell 10,000 shares of its common stock on Jul 1, with a total market value of approximately $1.38
FDA Sets Target Action Dates for Neurocrine Drug Applications